The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir

被引：9

作者：

Burger, David M.

Schwietert, H. Reinier

Colbers, E. P. H. Angela

Becker, Mark

机构：

[1] Radboud Univ, Med Ctr, NL-6525 GA Nijmegen, Netherlands

[2] Univ Nijmegen, Ctr Infect Dis, Nijmegen, Netherlands

[3] Xendo Drug Dev Serv, Groningen, Netherlands

[4] Farma Res, Nijmegen, Netherlands

[5] Roche Pharmaceut, Basel, Switzerland

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2006年 / 62卷 / 02期

关键词：

CYP2C19; PLASMA;

D O I：

10.1111/j.1365-2125.2006.02635.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：250 / 252

页数：3

共 9 条

[1] Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations [J].

Burger, DM ;

Hugen, PWH ;

Aarnoutse, RE ;

Hoetelmans, RMW ;

Jambroes, M ;

Nieuwkerk, PT ;

Schreij, G ;

Schneider, MME ;

van der Ende, ME ;

Lange, JMA .

THERAPEUTIC DRUG MONITORING, 2003, 25 (01) :73-80

[2] Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography [J].

Droste, JAH ;

Verweij-van Wissen, CPWGM ;

Burger, DM .

THERAPEUTIC DRUG MONITORING, 2003, 25 (03) :393-399

[3]

Furuta Takahisa, 2005, Drug Metab Pharmacokinet, V20, P153, DOI 10.2133/dmpk.20.153

[4]

HAAS DW, PHARMACOGENETICS LON

[5] Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19 [J].

Hirani, VN ;

Raucy, JL ;

Lasker, JM .

DRUG METABOLISM AND DISPOSITION, 2004, 32 (12) :1462-1467

[6] Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease [J].

Khaliq, Y ;

Gallicano, K ;

Seguin, I ;

Fyke, K ;

Carignan, G ;

Bulman, D ;

Badley, A ;

Cameron, DW .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 50 (02) :108-115

[7]

LILLIBRIDGE JH, 1998, 12 AAPS C

[8]

Ozawa Shogo, 2004, Drug Metab Pharmacokinet, V19, P83, DOI 10.2133/dmpk.19.83

[9] Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study) [J].

Pellegrin, I ;

Breilh, D ;

Montestruc, F ;

Caumont, A ;

Garrigue, I ;

Morlat, P ;

Le Camus, C ;

Saux, MC ;

Fleury, HJA ;

Pellegrin, JL .

AIDS, 2002, 16 (10) :1331-1340

← 1 →